Pharma channel feed

Biden ad­min­is­tra­tion in­vests $48M in AI/ML plat­form to iden­ti­fy rare dis­ease drugs

Last year
AI
FDA+

Sarep­ta touts Duchenne gene ther­a­py up­take, but warns of de­mand flat­ten­ing be­fore po­ten­tial ex­pand­ed la­bel from FDA

Last year
Cell/Gene Tx

Io­vance’s Am­tagvi sees ‘healthy de­mand’ af­ter US ap­proval

Last year
Cell/Gene Tx
Manufacturing

No­vo Nordisk plans for life af­ter We­govy, set­ting up roots in Boston to try and find its fu­ture

Last year
R&D

Ar­genx rolls out new cam­paign for rare au­toim­mune con­di­tion as it awaits FDA rul­ing

Last year
Marketing

Mod­er­na spells out rare dis­ease am­bi­tions: 'We have a bunch of INDs planned'

Last year
FDA+

Califf lays out drug short­age land­scape, talks post-mar­ket da­ta col­lec­tion for ac­cel­er­at­ed ap­provals

Last year
FDA+
Manufacturing

Jor­dan­ian OTC drug man­u­fac­tur­er re­ceives FDA warn­ing let­ter over mul­ti­ple ‘un­ac­cept­able haz­ards’

Last year
Manufacturing

Bris­tol My­ers eyes In­dia as home of its largest site out­side US by 2025, maps $400M Ire­land ex­pan­sion

Last year
R&D
Manufacturing

Ther­at­e­ch­nolo­gies hit with FDA refuse to file let­ter for in­tra­mus­cu­lar ver­sion of HIV drug

Last year
FDA+

Min­er­va's shares sink on re­jec­tion of schiz­o­phre­nia drug

Last year
FDA+

DOJ sub­poe­nas Bio­Marin over spon­sored test­ing pro­gram for rare dis­ease drugs

Last year
FDA+

Phar­ma con­sid­ers al­ter­na­tives to large sales forces

Last year
Marketing

Mar­ket­ingRx roundup: Pfiz­er talks about its ‘Char­lie’ AI mar­ket­ing bot; Gilead pledges $12M for HIV pre­ven­tion

Last year
Marketing

Roche is 'e­val­u­at­ing po­ten­tial op­tion­s' for IPF drug Es­bri­et as gener­ics gain trac­tion

Last year

No­vo Nordisk inks pact for dis­cov­ery of 'mol­e­c­u­lar glues' in deal worth as much as $1.46B

Last year
Deals

Rock­et Phar­ma to light up build­ings again for Rare Dis­ease Day as it awaits first FDA de­ci­sion

Last year
Marketing

FDA of­fi­cials, drug de­vel­op­ers dis­cuss how to stream­line safe­ty mon­i­tor­ing for bi­o­log­ics

Last year
FDA+

Fail­ure, faith and $8 bil­lion: How Lil­ly's amy­loid con­vic­tion brought it to the brink of Alzheimer's ap­proval

Last year
In Focus

Col­orado be­gins process to po­ten­tial­ly set pay­ment lim­it on Am­gen's arthri­tis drug En­brel

Last year

VML Health taps cre­ative lead­er­ship in wake of Wun­der­man and VM­LY&R merg­er

Last year
Marketing

New York AG calls for 'more strin­gen­t' Sin­gu­lair safe­ty warn­ings

Last year
FDA+

J&J to close Cal­i­for­nia R&D fa­cil­i­ty with plans to open new 'in­no­va­tion cen­ter'

Last year
R&D

Gilead bid against it­self in $4.3B deal for CymaBay, fil­ing shows

Last year
Deals
First page Previous page 68697071727374 Next page Last page
A service from the Financial Times